NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

Apolipoprotein E (ApoE) and Metabolism

CompletedN/A

Sponsor: Lance Johnson

Conditions: Cognitive Function, Healthy

Interventions: Resting State Indirect Calorimetry, ApoE, Metabolism, Cognitive Challenge

Countries: United States

Impaired metabolism and the gene apolipoprotein E (ApoE) are independent risk factors for cognitive impairment and dementia. In humans, there are three major versions of apoE (E): E2, E3, and E4. Some studies suggest that the different versions of apoE have varying effects on whole body and brain metabolism. The goal of this project is to better understand the relationship between apoE and metabolism. This will help investigators identify new targets for the prevention and treatment of cognitive decline and dementia.

Eligibility overview

Sex: ALL

Age: 18 Years to 65 Years

Study type: OBSERVATIONAL

Eligibility criteria

Inclusion Criteria:

* all races/ethnicities
* ages 18-65
* cognitively normal
* good health

Exclusion Criteria:

* pregnant or breastfeeding.
* have a bleeding disorder,
* have a history of stroke, seizures, Parkinson's disease, history of head injury with loss of consciousness, or other dementing disorder.
* have a history of alcoholism or drug abuse
* have a history of schizophrenia or currently suffer from bipolar disorder or major depression.
* have vision or hearing loss severe enough to interfere with cognitive testing

Locations (1)

Lexington, Kentucky, United States